Miran Ahmad
@Samsara Biocapital, Llc
Latest period2024 - Q3ReportedManaged Assets$520.277MTotal holdings42
Assets growth rate8.9%Assets growth rate (2-Q avg)-8.59%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Samsara Biocapital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 42 positions.
Assets under management
The assets under management (AUM) of Samsara Biocapital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 520.277M in assets, with a quarterly growth rate of 8.9% and a 2-quarter average growth rate of -8.59%. The portfolio is managed by Miran Ahmad, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CRGXCargo Therapeutics Inc
| 15.66% | $81.469M 4.416M shares@ $18.45 avg price | |
MLYSMineralys Therapeutics Inc
| 11.82% | $61.457M 5.075M shares@ $12.12 avg price | |
SRRKScholar Rock Hldg Corp
| 10.46% | $54.377M 6.789M shares@ $8.01 avg price | |
NGNENeurogene Inc
| 10.23% | $53.196M 1.268M shares@ $41.96 avg price | |
ALMSAlumis Inc
| 6.71% | $34.886M 3.266M shares@ $10.69 avg price | New Position |
ACLXArcellx Inc
| 5.68% | $29.533M 353,641 shares@ $83.52 avg price | Decreased -22.04% |
LENZLenz Therapeutics Inc
| 5.52% | $28.689M 1.208M shares@ $23.74 avg price | |
NKTXNkarta Inc
| 3.28% | $17.032M 3.768M shares@ $4.52 avg price | |
CLYMEliem Therapeutics Inc
| 2.56% | $13.28M 2.609M shares@ $5.09 avg price | Decreased -20% |
AVDLAvadel Pharmaceuticals Plc
| 2.44% | $12.689M 967,527 shares@ $13.12 avg price |